Recent developments in weight-loss medication include new restrictions on compounded GLP-1 drugs, which were created in response to a shortage declared by the FDA in 2022. While these alternatives were sold at lower prices by telehealth companies, a federal judge recently upheld the FDA's position that the shortage is over, leading to a halt in the production of these copycat medications. In contrast, brand-name drugs like Mounjaro and Ozempic continue to see significant sales increases, highlighting a strong market demand despite regulatory hurdles.
The FDA's declaration of a shortage led to compounded GLP-1 medications hitting the market, but a recent ruling sided with the FDA, ending this practice.
Despite the ban on copycat medications, sales of Mounjaro surged by 60% to $3.53 billion, underscoring the high demand for weight-loss drugs.
Collection
[
|
...
]